Circulation autoantibodies against C-terminus of NuMA in patients with Behçet's disease.
C-NuMA
antigen epitope site
autoantibody
nuclear protein
Journal
Central-European journal of immunology
ISSN: 1426-3912
Titre abrégé: Cent Eur J Immunol
Pays: Poland
ID NLM: 9702239
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
07
2017
accepted:
08
09
2017
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
20
5
2020
Statut:
ppublish
Résumé
Circulating autoantibodies have a close association with autoimmune diseases, which may be seen even in healthy individuals. These are also considered as promising source of new biomarkers in various autoimmune diseases. However, their profile is not completely understood till now. Here, we evaluated autoantibodies against nuclear mitotic apparatus protein located at the carboxy terminus (C-NuMA)in blood circulation of Han Chinese patients, using different technical approaches to discover pathological reaction leading to Behçet's disease (BD). In the first step, the recombinant human carboxy-terminal region of NuMA peptide (C-NuMA) was over-expressed and purified. In the second step, the indirect immunofluorescence method was used with patients' sera, and commercial anti-NuMA antibody was used to determine the NuMA as a potential autoantigen. Results were confirmed at cell level by western blots, indicating that two of ten patients with Behçet's disease could react with the recombinant C-NuMA,and the presence of antibodies were further verified by immunoprecipitation technique. Finally, the corresponding immunoassay (ELISA) was developed and optimized with specific recombinant C-NuMA as an in vitro method to test the confirmed patients with Behçet's disease. Our findings demonstrated that C-terminus of NuMA is an immune target of Behçet's disease in Han Chinese patients.
Identifiants
pubmed: 32425685
doi: 10.5114/ceji.2020.94710
pii: 94710
pmc: PMC7226561
doi:
Types de publication
Journal Article
Langues
eng
Pagination
86-92Informations de copyright
Copyright © 2020 Termedia.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Exp Cell Res. 2004 Aug 15;298(2):512-20
pubmed: 15265698
Microbiol Immunol. 2010 Jun;54(6):354-61
pubmed: 20536734
Rapid Commun Mass Spectrom. 2011 Jul 15;25(13):1862-8
pubmed: 21638362
Bioanalysis. 2012 Sep;4(17):2161-8
pubmed: 23013398
Biochem Biophys Res Commun. 2014 Aug 29;451(3):389-93
pubmed: 25091478
Virology. 2004 Mar 1;320(1):85-98
pubmed: 15003865
J Biol Chem. 2015 Jan 30;290(5):2593-603
pubmed: 25505266
Mol Biol Rep. 1995-1996;22(1):63-6
pubmed: 8858575
Lancet. 1990 May 5;335(8697):1078-80
pubmed: 1970380
Immunome Res. 2006 Apr 24;2:2
pubmed: 16635264
Autoimmun Rev. 2015 Jan;14(1):75-9
pubmed: 25449682
Front Biosci. 2006 Jan 01;11:1137-46
pubmed: 16146802
PLoS One. 2015 Apr 27;10(4):e0124760
pubmed: 25915519
Rheumatology (Oxford). 2006 Dec;45(12):1461-5
pubmed: 16998234
J Clin Immunol. 2008 Jul;28(4):285-90
pubmed: 18240009
Autoimmun Rev. 2010 Aug;9(10):652-6
pubmed: 20457279
Arthritis Rheum. 1996 Oct;39(10):1643-53
pubmed: 8843854
J Virol. 2015 Jun;89(11):5760-71
pubmed: 25810538
J Clin Invest. 1992 Sep;90(3):1061-6
pubmed: 1522214
Exp Cell Res. 1996 May 25;225(1):207-18
pubmed: 8635513
Sci Rep. 2015 Feb 02;5:8162
pubmed: 25641213
Oncotarget. 2016 Dec 6;7(49):80252-80261
pubmed: 27835913
Arthritis Rheum. 1984 Jul;27(7):774-9
pubmed: 6378210
J Autoimmun. 2010 Nov;35(3):276-90
pubmed: 20650611
Semin Arthritis Rheum. 2004 Oct;34(2):501-37
pubmed: 15505768
Trends Cell Biol. 1995 Feb;5(2):60-4
pubmed: 14731413
Arthritis Rheum. 2003 Jul;48(7):2025-35
pubmed: 12847697
Arthritis Rheum. 1996 Oct;39(10):1635-42
pubmed: 8843853
Biochem Biophys Res Commun. 2015 Jan 24;456(4):866-71
pubmed: 25529454
J Cell Sci. 2002 May 1;115(Pt 9):1815-24
pubmed: 11956313
J Invest Dermatol. 2012 Mar;132(3 Pt 1):601-8
pubmed: 22205302
Bioanalysis. 2013 Sep;5(18):2269-75
pubmed: 24053242